RegenMED MD
by Dr. Skinner

5590 E. RIVER RD, SUITE 150
TUCSON, AZ 85750
(520) 467-3015

Your Body's Blueprint For Healing

Top 10 Reasons to Choose Autologous SVF Harvesting & Exosome Delivery at RegenMED MD

Dr. David Skinner, MD | RegenMED MD | Catalina Foothills, Arizona

Welcome to a new era of personalized regenerative medicine. At RegenMED MD, we specialize in autologous Stromal Vascular Fraction (SVF) — a powerful concentrate of your own adipose-derived stem cells, pericytes, endothelial cells, and a rich cocktail of growth factors and cytokines — harvested gently from your fat tissue through a quick, minimally invasive procedure. We enhance this with exosomes, the sophisticated extracellular vesicles that serve as your cells' natural communication network, delivering regenerative signals, microRNAs, and proteins precisely where needed.

This document outlines the Top 10 Reasons this therapy stands apart, followed by the conditions we treat with expanded summaries of clinical evidence and key publications. Your own stem cells do the work — safely, effectively, and personally tailored to you. No foreign cells. No rejection risk. Just your biology, optimized.

THE TOP 10 REASONS

Why Patients and Physicians Choose SVF + Exosomes at RegenMED MD

1. **Truly Personalized & Safe**
   Your own cells eliminate rejection, allergic reactions, or compatibility issues. SVF is harvested from YOUR adipose tissue, processed same-day, and returned to YOU — the ultimate in personalized medicine. Autologous approach avoids all risks associated with allogeneic or cultured cells.

2. **Multi-Targeted Cellular Repair**
   SVF and exosomes simultaneously reduce chronic inflammation, promote angiogenesis (new blood vessels), support tissue regeneration, modulate immunity, and stimulate repair in brain, lungs, joints, and more — addressing the whole body through synergistic mechanisms.

3. **Disease-Modifying, Not Just Symptomatic**
   Unlike drugs that mask symptoms, this therapy targets root cellular dysfunction. Clinical evidence suggests potential to slow progression, stabilize, or improve function in neurodegenerative, autoimmune, and degenerative conditions (Duma et al., 2019; Comella et al., 2017).

4. **Outstanding Safety Profile**
   In a landmark multi-center analysis of 676 patients treated with autologous SVF for orthopedic, neurological, and systemic diseases, adverse events were minimal (3.4% minor, 0.59% serious — mostly unrelated). Excellent tolerability across age groups and conditions (Comella et al., 2017, J Clin Med Res). Neurological subgroups showed >84–96% safety.

5. **Precision Delivery Tailored to Your Condition**
   Joint Injection: Direct to knees, hips, shoulders, spine for localized repair. IV Infusion: Systemic for neurodegenerative, autoimmune, whole-body inflammation. Nebulization: Direct lung delivery for COPD, fibrosis — exosomes and cells reach alveoli efficiently. Combined routes often synergistic.

6. **Exosomes: The Regenerative Amplifier**
   Exosomes act as universal messengers, crossing the blood-brain barrier, delivering therapeutic cargo (miRNA, proteins, growth factors), and orchestrating repair even without cell engraftment. Combined with SVF, effects are broader, faster, and more profound. Systematic reviews confirm MSC-exosome potential in AD, PD, and other NDs (Quan et al., 2025; Chen et al., 2026).

7. **Broad, Evidence-Supported Applications**
   Robust clinical data and systematic reviews support benefits for Alzheimer's/dementia, Parkinson's, ALS, MS, COPD, rheumatoid arthritis, osteoarthritis, degenerative disc disease, chronic pain, and more — one versatile platform for multiple needs (Al-Kharboosh et al., 2022; Goncharov et al., 2024).

8. **Minimally Invasive, Same-Day Outpatient**
   Gentle mini-liposuction under local anesthesia (~45-60 min harvest). Immediate processing and delivery. No general anesthesia, no hospital stay, rapid recovery. Most patients resume normal activities within 24-48 hours. Point-of-care processing eliminates culturing risks.

9. **Potential for Lasting Regeneration**
   Improvements often build over weeks to months as your cells continue secreting factors and exosomes sustain signaling. Many patients report sustained pain relief, better function, and enhanced quality of life — true regeneration vs. temporary relief. Effects can strengthen over the first year.

10. **Expert, Compassionate Care at RegenMED MD**
    Led by Dr. David Skinner, we provide thorough evaluation, customized protocols, integration with your overall health plan, and dedicated follow-up. Science-backed hope delivered with genuine empathy and transparency. Every protocol personally overseen for your unique profile.

CONDITIONS WE TREAT

Evidence-Based Categories with Clinical Summaries & Citations

All therapies use your autologous SVF and/or exosomes. Results vary; these summaries highlight positive findings from peer-reviewed studies. Full references available.

1. NEURODEGENERATIVE DISEASES

Alzheimer's Disease, Dementia, Parkinson's Disease, ALS, Multiple Sclerosis, Stroke Recovery, Cognitive Decline

Mechanism: SVF stem cells and exosomes reduce neuroinflammation, promote neurogenesis, protect neurons, clear misfolded proteins (e.g., amyloid-β in AD, α-synuclein in PD), and support blood-brain barrier integrity. IV and intrathecal routes allow CNS access; exosomes particularly excel at crossing barriers and delivering miRNA cargo. Autologous SVF provides a living, dynamic source of multiple cell types plus paracrine factors.

Key Evidence:

- Duma et al. (2019) — 3-year Phase 1 ICV autologous ADSVF study in 31 patients with neurodegenerative disorders (including 10 with AD). 113 injections, excellent safety; several AD patients showed cognitive stabilization/improvement and reduced CSF biomarkers (Mol Biol Rep).
- Shigematsu et al. (CTAD 2021) — Repeated IV autologous ADSC administration improved ADAS-Cog scores in mild-moderate AD patients with no serious adverse events.
- Li R et al. (2026) — Prospective study of 26 ALS patients receiving autologous SVF (IV + intrathecal): no serious adverse events, partial symptom improvement in 15 participants, with immunomodulation and neuroprotection (Front Aging Neurosci).
- Comella et al. (2017) — Landmark analysis of 676 patients (including PD, MS, dementia, TBI cases): >96% overall safety, reported functional gains in neurological subgroup (J Clin Med Res).
- Exosome Reviews (Quan et al. 2025; Liu et al. 2022; Chen et al. 2026) — Systematic reviews confirm MSC-exosomes cross BBB, reduce amyloid/tau pathology, and show strong therapeutic signals in preclinical AD/PD models with emerging clinical translation (Stem Cell Res Ther; Front Neurol; Neural Regen Res).

Positive Interpretation: For conditions once considered relentlessly progressive, your own cells and exosomes offer a powerful new tool — potentially slowing decline, stabilizing function, and in some cases restoring lost ground in cognition, mobility, and daily independence. Early intervention maximizes potential. Emerging data position autologous SVF + exosomes as a promising disease-modifying approach for Alzheimer's, dementia, and related conditions.

2. LUNG & RESPIRATORY CONDITIONS

COPD, Pulmonary Fibrosis, Chronic Bronchitis, Emphysema, Long COVID Lung Issues, Refractory Asthma

Mechanism: Nebulized SVF/exosomes deliver directly to airways and alveoli for local anti-inflammatory, anti-fibrotic, and reparative effects. IV provides systemic support. Reduces oxidative stress, modulates immune hyperactivity, and may aid alveolar repair and vascular regeneration in damaged lung tissue.

Key Evidence:

- Comella et al. (2017) — Dedicated Phase I trial of autologous SVF IV infusion in end-stage COPD: excellent safety (no serious adverse events) and signals of improved quality of life (J Clin Med Res — pulmonary-specific).
- Nguyen et al. (2021) — Case series of autologous adipose-derived stem cells in COPD: demonstrated safety and partial functional improvement.
- Sun et al. (2018) & ERJ Open Research 2023 reviews — Clinical programs combining IV + nebulized adipose-derived cells report up to 82% of patients with noticeable QoL improvements and slower decline vs. natural history; MSC/SVF shows promise in reducing inflammation and supporting lung tissue repair.

Positive Interpretation: Breathe easier and live fuller. Patients often report less shortness of breath, better stamina, and improved daily function as inflammation calms and repair processes activate — a regenerative option for lungs previously managed only symptomatically.

3. AUTOIMMUNE & INFLAMMATORY DISEASES

Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), SLE, Crohn's, Psoriasis, Hashimoto's, Mixed Connective Tissue Disease

Mechanism: SVF's mix of mesenchymal stem cells, regulatory T-cells, and cytokines rebalances overactive immunity, promotes tolerance, reduces autoantibody-driven damage, and repairs affected organs/tissues. Exosomes amplify anti-inflammatory signaling and immunomodulation without broad immunosuppression.

Key Evidence:

- Comella et al. (2017) — 676-patient analysis included multiple autoimmune and MS cases: high safety profile (>90%) and reported clinical benefits in neurological/autoimmune subgroups (J Clin Med Res).
- Minev et al. case series — Early SVF series in MS patients achieved remission or dramatic seizure/mobility gains.
- Additional supporting data — Autologous adipose MSCs/SVF showed clinical improvement and immune modulation in RA and coexisting autoimmune thyroiditis (case reports with objective markers); broader reviews confirm safety and immunomodulatory potential (Ra JC et al. 2011; Mohammedsaleh 2022). Ongoing trials for expanded autologous AD-MSCs in RA show encouraging signals.

Positive Interpretation: Reset your immune system naturally. Many patients experience reduced flares, lower medication needs, and improved energy/joint health — moving from disease management toward remission using the healing intelligence already inside you.

4. JOINT, SPINE & MUSCULOSKELETAL CONDITIONS

Knee/Hip/Shoulder Osteoarthritis, Degenerative Disc Disease (DDD), Herniated Discs, Spinal Stenosis, Chronic Low Back/Neck Pain, Tendinopathy, Sports Injuries

Mechanism: Targeted intra-articular or fluoroscopy-guided peridiscal injections deliver high concentrations of regenerative cells and exosomes directly to cartilage, synovium, discs, and ligaments. Promotes matrix synthesis (collagen, proteoglycans), reduces catabolic enzymes, calms local inflammation, and supports angiogenesis for tissue repair.

Key Evidence — Joints:

- Boada-Pladellorens et al. (2022) — Systematic review & meta-analysis of SVF for knee OA (9+ RCTs, hundreds of patients): confirmed safety and significant improvements in pain (VAS) and function (WOMAC) at 3, 6, and 12 months — often superior to hyaluronic acid or saline (Medicina).
- Mehling et al. (2020) — 350-patient retrospective study: sustained mobility and pain gains in hip and knee OA (J Clin Med Res).
- Goncharov et al. (2023/2024) & recent 2025 RCTs — Reviews and trials confirm MRI cartilage signal improvement/preservation and long-term functional benefits.

Key Evidence — Spine:

- Zhou et al. (2025) & emerging clinical data — Exosome and SVF therapies for intervertebral disc degeneration (IVDD) support nucleus pulposus cell survival, reduced inflammation, and pain relief. Direct injection protocols for DDD and herniated discs show promise for restoring disc health and alleviating *radiculopathy.*

Positive Interpretation: Reclaim movement without surgery or endless NSAIDs. Patients frequently report walking farther, sleeping better, and returning to hobbies as their own biology rebuilds joint and disc integrity — often with effects that strengthen over the first year.

5. ADDITIONAL APPLICATIONS

Key Evidence:

- Cardiovascular & Metabolic — Early trials and case series show improved perfusion, reduced fibrosis post-MI, and benefits in diabetic neuropathy/ulcers and peripheral artery disease via angiogenesis and tissue repair.
- Urological (ED & Peyronie's) — SVF demonstrates promise in vascular regeneration and tissue repair for erectile dysfunction and Peyronie's disease.
- Anti-Aging & Other — Growing evidence for systemic rejuvenation, skin/hair quality, cognitive sharpness, chronic fatigue, fibromyalgia, and post-viral syndromes (Al-Kharboosh et al. 2022; Goncharov et al. 2024).

WHY YOUR OWN STEM CELLS & EXOSOMES ARE UNIQUELY POWERFUL

Autologous SVF is not a drug — it is a living, dynamic therapeutic ecosystem derived from you. It contains multiple stem cell types (ADSCs, pericytes, endothelial progenitors) plus supporting cells that work synergistically. Exosomes serve as the "software update" for your cells, carrying precise instructions for repair without the limitations of whole-cell engraftment or the risks of cultured/expanded cells (contamination, senescence, immunogenicity). This combination is:

- **Safe:** No immunosuppression needed; minimal immunogenicity. Landmark data: 3.4% minor AEs in 676 patients (Comella et al., 2017).
- **Potent:** Rich cytokine milieu + targeted exosome signaling + multi-lineage cells for comprehensive repair.
- **Convenient:** Point-of-care, same-day processing — no culturing delays, no foreign additives, repeatable if needed.
- **Ethical & Sustainable:** Your body, your healing — no ethical concerns of embryonic or allogeneic sources.

At RegenMED MD, we optimize every step: precise harvesting technique, validated processing for high viable cell yield (>90% viability typical), and strategic delivery (often combining routes for synergistic effect). Dr. Skinner personally oversees protocols to match your unique health profile.

TAKE THE NEXT STEP

Your journey to regeneration begins with a personalized consultation. Dr. David Skinner will review your medical history, discuss realistic expectations, and design a protocol tailored to your goals — whether joint restoration, cognitive support, breathing easier, or systemic rejuvenation. Call 520-467-3015 or visit www.regenmedmd.com to schedule.

SELECTED REFERENCES ***(Patients Encouraged to Review)***

1. Comella K, et al. Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases... J Clin Med Res. 2017;9(10):841-849. https://www.jocmr.1. Comella K, et al. Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases... J Clin Med Res. 2017;9(10):841-849. https://www.jocmr.org/index.php/JOCMR/article/view/3187 (676 patients, broad safety).
2. Duma C, et al. Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients. Mol Biol Rep. 2019;46(5):5067-5076. doi:10.1007/s11033-019-04983-5.
3. Al-Kharboosh R, et al. Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction. Clin Transl Med. 2022;12(9):e1093. doi:10.1002/ctm2.1093.
4. Boada-Pladellorens A, et al. Stromal vascular fraction therapy for knee osteoarthritis: a systematic review. Medicina (Kaunas). 2022;58(10):1393. PMC9386815.
5. Mehling B, et al. Retrospective Study of SVF Cell Therapy in Hip and Knee OA (350 subjects). J Clin Med Res. 2020;12(3):157-165.
6. Li R, et al. Autologous Stromal Vascular Fraction Modulates Neuroinflammation in ALS Patients. Front Aging Neurosci. 2026.
7. Quan J, et al. Mesenchymal stem cell exosome therapy: current research status in the treatment of neurodegenerative diseases... Stem Cell Res Ther. 2025;16(1):41.
8. Liu S, et al. Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review. Front Neurol. 2022;13:950715.
9. Comella K, et al. Autologous Stromal Vascular Fraction in the Intravenous Treatment of End-Stage Chronic Obstructive Pulmonary Disease: A Phase I Trial. J Clin Med Res. 2017;9(7):605-612.
10. Goncharov EN, et al. Analyzing the Clinical Potential of Stromal Vascular Fraction. Medicina. 2024;60(2):312.
11. Shah S, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles as a Promising Alternative in the Therapy of Alzheimer's Disease. 2024.
12. Chen H, et al. Exosomes in neurodegenerative diseases: Therapeutic strategies and challenges. Neural Regen Res. 2026.
13. Shigematsu K, et al. Repeated administration of autologous adipose tissue-derived stem cells improved cognitive function in Alzheimer disease. Presented at: 14th Clinical Trials on Alzheimer's Disease (CTAD); November 2021.
14. Nguyen TT, et al. Autologous adipose-derived stem cells therapy in COPD: a case report. 2021.
15. Sun Z, et al. Stem cell therapies for chronic obstructive pulmonary disease. J Thorac Dis. 2018;10(Suppl 20):S2345-S2356.